A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
Phase of Trial: Phase III
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Alpelisib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 03 May 2019 Planned primary completion date changed from 1 May 2018 to 1 May 2020.
- 31 Aug 2018 Biomarkers information updated
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.